Inactivation and modification of superoxide dismutase by glyoxal: Prevention by antibodies

Biochimie

Volumn 89, Issue 3, 2007, Pages 311-318

  Jabeen, Rukhsana ^a,b   Saleemuddin, M ^b   Petersen, John ^a   Mohammad, Amin ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Glyoxal; Maillard reaction; Polyclonal antibodies; SOD

Indexed keywords

ENZYME ANTIBODY; GLYOXAL; IMMUNOGLOBULIN F(AB) FRAGMENT; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME GLYCOSYLATION; ENZYME INACTIVATION; ENZYME MODIFICATION; ENZYME REGULATION; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN CROSS LINKING; SPECTROPHOTOMETRY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ANIMALS; ANTIBODIES; CATTLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME ACTIVATION; ERYTHROCYTES; GLYCOSYLATION END PRODUCTS, ADVANCED; GLYOXAL; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; RABBITS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUPEROXIDE DISMUTASE;

EID: 33947371321     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2006.10.015     Document Type: Article

References (59)

1. Brownlee M. The pathological implications of protein glycation. Clin. Invest. Med. 18 (1995) 275-281
2. Cerami A., and Ulrich P. Pharmaceutical intervention of advanced glycation end products. Novartis Found. Symp. 235 (2001) 202-212
3. Neglia C.I., Cohen H.J., Garber A.R., Ellis P.D., Thorpe S.R., and Baynes J.W. NMR investigation of nonenzymatic glucosylation of protein. Model studies using RNase A. J. Biol. Chem. 258 (1983) 14279-14283
4. Baynes J.W., Watkins N.G., Fisher C.I., Hull C.J., Patrick J.S., Ahmed M.U., Dunn J.A., and Thorpe S.R. The Amadori product on protein: structure and reactions. Prog. Clin. Biol. Res. 304 (1989) 43-67
5. Liggins J., and Furth A.J. Role of protein-bound carbonyl groups in the formation of advanced glycation end products. Biochim. Biophys. Acta 1361 (1997) 123-130
6. Stitt A.W., Jenkins A.J., and Cooper M.E. Advanced glycation end products and diabetic complications. Expert. Opin. Investig. Drugs 11 (2002) 1205-1223
7. Thornalley P.J., Langborg A., and Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344 (1999) 109-116
8. Wells-Knecht K.J., Zyzak D.V., Lichtfield J.E., Thorpe S.R., and Baynes J.W. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34 (1995) 3702-3709
9. Dudda A., Spiteller G., and Kobelt F. Lipid oxidation products in ischemic porcine heart tissue. Chem. Phys. Lipids 82 (1996) 39-51
10. Fu M.X., Requena J.R., Jenkins A.J., Lyons T.J., Baynes J.W., and Thorpe S.R. The advanced glycation end product, N-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271 (1996) 9982-9986
11. Shibamoto T. The role of lipid peroxidation caused by ultraviolet light in skin diseases. J. Toxicol., Cutan. Ocul. Toxicol. 13 (1994) 193-202
12. Murata-Kamiya N., Kamiya H., Iwamoto N., and Kasai H. Formation of a mutagen, glyoxal, from DNA treated with oxygen free radicals. Carcinogenesis 16 (1995) 2251-2253
13. Lederer M.O., and Klaiber R.G. Cross-linking of proteins by Maillard processes: characterization and detection of lysine-arginine cross-links derived from glyoxal and methylglyoxal. Bioorg. Med. Chem. 11 (1999) 2499-2507
14. ω-carboxymethylarginine as a novel acid-labile advanced glycation end product in collagen. Biochem. J. 347 (2000) 23-27
15. Brock J.W., Hinton J.S., Cotham W.E., Metz T.O., Thorpe S.R., Baynes J.W., and Ames J.M. Proteomic analysis of the site specificity of glycation and carboxymethylation of ribonuclease. J. Proteome Res. 12 (2003) 506-513
16. Thornalley P.J. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int. Rev. Neurobiol. 50 (2002) 37-57
17. Zeng J., and Davies M.J. Evidence for the formation of adducts and S-(carboxymethyl) cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem. Res. Toxicol. 18 (2005) 1232-1241
18. Roberts M.J., Wondrak G.T., Laurean D.C., Jacobson M.K., and Jacobson E.L. DNA damage by carbonyl stress in human skin cells. Mutat. Res. 522 (2003) 45-46
19. Murata-Kamiya N., Kaji H., and Kasai H. Types of mutation induced by glyoxal, a major oxidative DNA damage product, in Salmonella typhimurium. Mutat. Res. 37 (1997) 13-16
20. Murata-Kamiya N., Kamiya H., Kaji H., and Kasai H. Glyoxal, a major product of DNA oxidation, induces mutation at G:C sites on a shuttle vector plasmid replicated in mammalian cells. Nucleic Acids Res. 25 (1997) 1897-1902
21. Abordo E.A., Minhas H.S., and Thornalley P.J. Accumulation of α-oxoaldehydes during oxidative stress: a role in cytotoxicity. Biochem. Pharmacol. 58 (1999) 641-648
22. Lapolla A., Flamini R., Dalla Vedova A., Senesi A., Reitano R., Fedele D., Basso E., Seraglia R., and Traldi P. Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin. Chem. Lab. Med. 41 (2003) 1166-1173
23. Agalou S., Ahmed N., Dawnay A., and Thornalley P.J. Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis. Biochem. Soc. Trans. 31 (2003) 1394-1396
24. Miyata T., and Kurokawa K. Carbonyl stress: increased carbonyl modification of proteins by autoxidation products of carbohydrates and lipids in uremia. Int. J. Artif. Organs 22 (1999) 195-198
25. Cotham W.E., Metz T.O., Ferguson P.L., Brock J.W., Hinton D.J., Thorpe S.R., Baynes J.W., and Ames J.M. Proteomic analysis of arginine adducts on glyoxal-modified ribonuclease. Mol. Cell. Proteomics 3 (2004) 1145-1153
26. Mikulikova K., Miksik I., and Deyl Z. Non-enzymatic posttranslational modifications of bovine serum albumin by oxo-compounds investigated by chromatographic and electrophoretic methods. J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci. 815 (2005) 315-331
27. Kasper M., Roehlecke C., Witt M., Fehrenbach H., Hofer A., Miyata T., Weigert C., Funk R.H., and Schleicher E.D. Induction of apoptosis by glyoxal in human embryonic lung epithelial cell line L132. Am. J. Respir. Cell Mol. Biol. 23 (2000) 485-491
28. Sady C., Jiang C.L., Chellan P., Madhun Z., Duve Y., Glomb M.A., and Nagaraj R.H. Maillard reactions by alpha-oxoaldehydes: detection of glyoxal-modified proteins. Biochim. Biophys. Acta 29 (2000) 255-264
29. Arai K., Maguchi S., Fujii S., Ishibashi H., Oikawa K., and Taniguchi N. Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites. J. Biol. Chem. 262 (1987) 16969-16972
30. Jabeen R., and Saleemuddin M. Polyclonal antibodies inhibit the glycation-induced inactivation of bovine Cu,Zn-superoxide dismutase. Biotechnol. Appl. Biochem. 43 (2006) 49-53
31. Stults N.L., Asta L.M., and Lee Y.C. Immobilization of proteins on oxidized crosslinked Sepharose preparations by reductive amination. Anal. Biochem. 180 (1989) 114-119
32. Nishikimi M., Appaji N., and Yagi K. The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem. Biophys. Res. Commun. 46 (1972) 849-854
33. Solomon B., and Schwartz F. Chaperone-like effect of monoclonal antibodies on refolding of heat-denatured carboxypeptidase A. J. Mol. Recognit. 8 (1995) 72-76
34. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H.P., Giardino I., and Brownle M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 (2000) 787-790
35. Rosca M.G., Mustata T.G., Kinter M.T., Ozdemir A.M., Kern T.S., Szweda L.I., Brownlee M., Monnier V.M., and Weiss M.F. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am. J. Physiol. Renal Physiol. 289 (2005) 420-430
36. Ramasamy R., Vannucci S.J., Yan S.S., Herold K., Yan S.F., and Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 7 (2005) 16-28
37. Kasper M., and Funk R.H.W. Age-related changes in cells and tissues due to advanced glycation end products (AGEs). Arch. Gerontol. Geriat. 32 (2001) 233-243
38. Alberts B., Johnson A., Lewis J., Raff M., Roberts K., and Walter P. Molecular Biology of the Cell. fourth ed. (2002), Garland, New York
39. Stitt A.W. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp. Mol. Pathol. 75 (2003) 95-108
40. Yan H., and Harding J.J. The molecular chaperone, alpha-crystallin, protects against loss of antigenicity and activity of esterase caused by sugars, sugar phosphate and a steroid. Biol. Chem. 384 (2003) 1185-1194
41. Ganea E., and Harding J.J. Molecular chaperones protect against glycation-induced inactivation of glucose-6-phosphate dehydrogenase. Eur. J. Biochem. 231 (1995) 181-185
42. Ukeda H., Hasegawa Y., Ishi T., and Sawamura M. Inactivation of Cu,Zn-superoxide dismutase by intermediates of Maillard reaction and glycolytic pathway and some sugars. Biosci. Biotechnol. Biochem. 12 (1997) 2039-2042
43. Ermolenko D.N., Zherdev A.V., and Dzantiev B.B. Antibodies as specific chaperones. Biochemistry 69 (2004) 1233-1238
44. Derham B.K., Ellory J.C., Bron A.J., and Harding J.J. The molecular chaperone alpha-crystallin incorporated into red cell ghosts protects membrane Na/K-ATPase against glycation and oxidative stress. Eur. J. Biochem. 270 (2003) 2605-2611
45. Ulbrich-Hofman R., Golbik R., and Damerau W. In: Vander Tweel W.J.J., Harder A., and Buitelar R.M. (Eds). Stability Sand Stabilization of Enzymes (1993), Elsevier, Amsterdam 497-504
46. Younus H., Owais M., Rao D.N., and Saleemuddin M. Stabilization of pancreatic ribonuclease A by immobilization on Sepharose-linked antibodies that recognize the labile region of the enzyme. Biochim. Biophys. Acta 36454 (2001) 1-7
47. Blond S., and Goldberg M. Partly native epitopes are already present on early intermediates in the folding of tryptophan synthase. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 1147-1151
48. Xu Q., Xie Z., Ding J., Lin S.X., and Xu G. Monoclonal antibodies assisting refolding of firefly luciferase. Protein Sci. 7 (2004) 1851-1858
49. Sanz L., Cuesta A.M., Compte M., and Alvarez-Vallina L. Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol. Sin. 6 (2005) 641-648
50. Gupta P., Khan R.H., and Saleemuddin M. Binding of antibromelain monomeric Fab' improves the stability of stem bromelain against inactivation. Biochim. Biophys. Acta 1646 (2003) 131-135
51. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
52. Muzykantov V.R. Targeting of superoxide dismutase and catalase to vascular endothelium. J. Control. Release 71 (2001) 1-21
53. Rengel R.G., Filipovic-Grcic J., Cepelak I., Zanic-Grubisic T., and Barisic K. The effect of liposomes with superoxide dismutase on A2182 cells. Eur. J. Pharm. Biopharm. 60 (2005) 47-51
54. Ratnam D.D., Ankola D.D., Bhardwaj V., Sahana D.K., and Ravikumar M.N.V. Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. J. Control. Release 113 (2006) 189-207
55. Eum W.S., Choung I.S., Li M.Z., Kang J.H., Kim D.W., Park J., Kwon H.Y., and Choi S.Y. HIV-1 TAT-mediated protein transduction of Cu,Zn-Superoxide dismutase into pancreatic β cells in vitro and in vivo. Free Radic. Biol. Med. 37 (2004) 339-349
56. Kim H.A., Kim D.W., Park J., and Choi S.Y. Transduction of Cu,Zn-superoxide dismutase mediated by an HIV-1 TAT protein basic domain into chondrocytes. Arthritis Res. Ther. 8 (2006)
57. Heng B.C., and Cao T. Making cell-permeable antibodies (transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies. Potential advantages over antibodies expressed within the intracellular environment (Intrabody). Med. Hypotheses 64 (2005) 1105-1108
58. Kontermann R.E. Intrabodies as therapeutic agents. Methods 34 (2004) 163-170
59. Lobato M.N., and Rabbitts T.H. Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules. Curr. Mol. Med. 4 (2004) 519-528